UK MHRA Authorization and NICE Guidance for Myqorzo Add Ex-US Credibility, but Thesis Hinges on US Launch and ACACIA Data

What happened

Cytokinetics secured UK MHRA marketing authorization for Myqorzo (aficamten) in symptomatic obstructive HCM and positive NICE guidance, extending the drug’s global regulatory footprint beyond the US, China, and a pending EU decision. This milestone adds a small, reimbursed market in England and Wales, incrementally supporting management’s Vision 2030 strategy but representing only a fraction of the revenue model. The core investment thesis remains dominated by the heavy-lift U.S. launch against Bristol Myers Squibb’s entrenched Camzyos, where Myqorzo must demonstrate real-world switching and new-patient capture to justify premium valuation. The company’s fragile balance sheet—negative equity and high cash burn—still requires robust commercial traction and a positive ACACIA nHCM readout in Q2 2026 to avoid dilutive recapitalization. Consequently, this UK news, while positive, does not alter the risk-reward skew that underpins the master report’s cautious stance.

Implication

In the near term, this news is unlikely to materially shift valuation given the UK's smaller market size relative to the U.S. opportunity. The deep value report's bear case at $40 still reflects substantial downside if Myqorzo fails to dislodge Camzyos or if ACACIA disappoints, risks untouched by this milestone. Positive NICE guidance may support pricing but doesn't guarantee rapid uptake; the company must still prove commercial capability against Bristol's entrenched position. Over the next 12-18 months, the stock's direction will be determined by Myqorzo's US sales trajectory and the binary ACACIA outcome, not by incremental ex-US approvals. Investors should continue to focus on quarterly prescription data and the Q2 2026 data readout, as the thesis remains heavily contingent on these catalysts.

Thesis delta

The UK authorization aligns with the already anticipated ex-US expansion; it doesn't shift the thesis's core risks. The investment case still depends on overcoming Camzyos competition and achieving a positive ACACIA trial, while the balance sheet remains vulnerable.